Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
27 hedge funds and large institutions have $37.6M invested in Eagle Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
51% more capital invested
Capital invested by funds: $25M → $37.6M (+$12.6M)
8.79% more ownership
Funds ownership: 12.43% → 21.22% (+8.8%)
4% less funds holding
Funds holding: 28 → 27 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$7.61M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$2.98M |
| 3 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$1.65M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$705K |
| 5 |
D.E. Shaw & Co
New York
|
+$439K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$444K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$206K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$173K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$142K |
| 5 |
Barclays
London,
United Kingdom
|
-$113K |
EGRX Hedge Fund Activity: Q3 2014 in Review
27 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2014, worth a combined $37.6M — up 51% from $25M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of EGRX and 9 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was Jennison Associates, adding an estimated $7.61M. The largest seller was Northern Trust, exiting entirely with an estimated $444K sold.
- 27 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2014, down from 28 in Q2 2014.
- Funds reported $37.6M of Eagle Pharmaceuticals, Inc. stock for Q3 2014, up 51% quarter-over-quarter.
- 9 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2014 and 10 closed out, a net change of -1 holder.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2014 was Jennison Associates, an estimated $7.61M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2014 was Northern Trust, an estimated $444K sold.
Based on aggregated 13F filings for Q3 2014.